Last Updated on October 17, 2024 by The Health Master
CSIR-Central Drug Research Institute’s (CDRI) osteoporosis drug will be the first drug of the institute to be used by patients in the US.
CDRI has given the license of its patented drug Caviunin Scaffold to Aveta Biomics, which is a leader in developing the next generation of botanical drugs for its development and commercialization.
Caviunin Scaffold, launched in 2015, has broad applications for bone health that include its efficacy in treating osteoporosis, fracture healing, osteoarthritis and other endocrinological conditions.
The drug has dual benefits as it helps both in bone formation and also bone resorption (break down the tissues in bones).
“Scaffold has a targetted action that prevents bone breakdown, stimulates new bone formation and reduces bone clinical markers.
The licence to Aveta Biomics is a testament to the calibre of our innovative science and demonstrates the value of the strong research,” said principal scientist Ritu Trivedi, who led the osteoporosis drug research.
Professor Tapas Kundu, Director, CSIR-CDRI, said, “We joined hands with Aveta Biomics given their track record of obtaining four clinical Investigational New Drug (IND) applications of their botanical drugs and for several cancer indications from the US Food and Drug Administration (UFDA).
We expect, therefore, translation of CDRI’s research into real drugs for people living with bone-related conditions not only in India, but abroad also.”
Adding to it, Parag G Mehta, CEO, Aveta Biomics, said, “Osteoporosis is a chronic condition requiring life-long treatment. The approved treatment duration of the currently available drugs ranges from one-to-five years (depending on the drug) due to waning efficacy and an increased risk of adverse events. “Caviunin-based therapeutics have a huge potential to change the standard of care for osteoporosis.”
Govt to include Acitretin in Schedule H of Drugs Rules, 1945
DoP revises list of Medical Devices for which no local manufacturers…
Stop use of Kanamycin injection: TB activists
IPC to develop & revise IP general chapters, Monographs
USFDA gives nod to Granules India for generic antidepressant drug
NPPA extends trade margin capping on these 5 Medical Devices
Pharma Companies to pay $590 mn to US Native Americans over opioids
USFDA gives tentative nod to Alembic for Fesoterodine fumarate extended-release tablets
Freebies to doctors at your own cost, Pharma companies told
Latest Notifications regarding Pharmaceuticals
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
